283 related articles for article (PubMed ID: 35547245)
1. Prognostic Value of Drug Targets Predicted Using Deep Bioinformatic Analysis of m6A-Associated lncRNA-Based Pancreatic Cancer Model Characteristics and Its Tumour Microenvironment.
Cao PW; Liu L; Li ZH; Cao F; Liu FB
Front Genet; 2022; 13():853471. PubMed ID: 35547245
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of N6-Methyladenosine-Related lncRNAs in Early-Stage Colorectal Cancer: Association With Immune Cell Infiltration and Chemotherapeutic Drug Sensitivity.
Xiong Z; Li X; Yin S; Xie M; Mao C; Zhang F; Chen H; Jin L; Lian L
Front Mol Biosci; 2021; 8():724889. PubMed ID: 34712696
[No Abstract] [Full Text] [Related]
3. Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer.
Wang Y; Zhu GQ; Tian D; Zhou CW; Li N; Feng Y; Zeng MS
BMC Cancer; 2022 Mar; 22(1):316. PubMed ID: 35331183
[TBL] [Abstract][Full Text] [Related]
4. Analysis of N6-methyladenosine-related lncRNAs in the tumor immune microenvironment and their prognostic role in pancreatic cancer.
Liu Y; Wang T; Fang Z; Kong J; Liu J
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1613-1626. PubMed ID: 35314871
[TBL] [Abstract][Full Text] [Related]
5. Relationships of N6-Methyladenosine-Related Long Non-Coding RNAs With Tumor Immune Microenvironment and Clinical Prognosis in Lung Adenocarcinoma.
Zhao J; Lin X; Zhuang J; He F
Front Genet; 2021; 12():714697. PubMed ID: 34777460
[No Abstract] [Full Text] [Related]
6. Identification of N6-Methyladenosine-Associated Long Non-coding RNAs for Immunotherapeutic Response and Prognosis in Patients With Pancreatic Cancer.
Yu X; Dong P; Yan Y; Liu F; Wang H; Lv Y; Song M; Yao Q; Hu S
Front Cell Dev Biol; 2021; 9():748442. PubMed ID: 34621754
[TBL] [Abstract][Full Text] [Related]
7. Identification of a novel m6A-related lncRNAs signature and immunotherapeutic drug sensitivity in pancreatic adenocarcinoma.
Li XQ; Yin SQ; Chen L; Tulamaiti A; Xiao SY; Zhang XL; Shi L; Miao XC; Yang Y; Xing X
BMC Cancer; 2024 Jan; 24(1):116. PubMed ID: 38262966
[TBL] [Abstract][Full Text] [Related]
8. Construction of a cancer-associated fibroblasts-related long non-coding RNA signature to predict prognosis and immune landscape in pancreatic adenocarcinoma.
Ye Y; Zhao Q; Wu Y; Wang G; Huang Y; Sun W; Zhang M
Front Genet; 2022; 13():989719. PubMed ID: 36212154
[No Abstract] [Full Text] [Related]
9. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
[TBL] [Abstract][Full Text] [Related]
10. Analysis of m
Wu X; Wang S; Wu X; Chen Q; Cheng J; Qi Z
J Cancer; 2024; 15(7):2045-2065. PubMed ID: 38434979
[No Abstract] [Full Text] [Related]
11. m6A-immune-related lncRNA prognostic signature for predicting immune landscape and prognosis of bladder cancer.
Feng ZH; Liang YP; Cen JJ; Yao HH; Lin HS; Li JY; Liang H; Wang Z; Deng Q; Cao JZ; Huang Y; Wei JH; Luo JH; Chen W; Chen ZH
J Transl Med; 2022 Oct; 20(1):492. PubMed ID: 36309694
[TBL] [Abstract][Full Text] [Related]
12. Integrated risk scores from N6-methyladenosine-related lncRNAs are potential biomarkers for predicting the overall survival of bladder cancer patients.
Huang X; Wang HF; Huang S
Front Genet; 2022; 13():906880. PubMed ID: 36061188
[No Abstract] [Full Text] [Related]
13. Comprehensive Analysis of N6-Methylandenosine-Related Long Non-Coding RNAs Signature in Prognosis and Tumor Microenvironment of Bladder Cancer.
Chen K; Zhu S; Yu W; Xia Y; Xing J; Geng J; Cheng F
Front Oncol; 2022; 12():774307. PubMed ID: 35141159
[TBL] [Abstract][Full Text] [Related]
14. N6-methylandenosine-related lncRNAs play an important role in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma.
Hu Y; Chen Y
Sci Rep; 2021 Sep; 11(1):17844. PubMed ID: 34497315
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive Analysis of N6-Methyladenosine-Related IncRNAs Prognostic Signature and the Associated Immune Infiltrates in Kidney Renal Clear Cell Carcinoma.
Chen X; Wang L; Tu J; Pan X; Li Y; Yin H; Wang M; Yuan X
Crit Rev Eukaryot Gene Expr; 2022; 32(1):79-98. PubMed ID: 35377983
[TBL] [Abstract][Full Text] [Related]
16. N6-Methylandenosine-Related lncRNAs Predict Prognosis and Immunotherapy Response in Bladder Cancer.
Zhang Y; Zhu B; He M; Cai Y; Ying X; Jiang C; Ji W; Zeng J
Front Oncol; 2021; 11():710767. PubMed ID: 34458149
[TBL] [Abstract][Full Text] [Related]
17. m6A-related long noncoding RNAs predict prognosis and indicate therapeutic response in endometrial carcinoma.
Zhou X; Zhang H; Duan Y; Zhu J; Dai H
J Clin Lab Anal; 2023 Jan; 37(1):e24813. PubMed ID: 36525280
[TBL] [Abstract][Full Text] [Related]
18. Construction of an N6-methyladenosine lncRNA- and immune cell infiltration-related prognostic model in colorectal cancer.
Yu ZL; Zhu ZM
Protoplasma; 2022 Jul; 259(4):1029-1045. PubMed ID: 34734333
[TBL] [Abstract][Full Text] [Related]
19. Identification of N6-methylandenosine related lncRNA signatures for predicting the prognosis and therapy response in colorectal cancer patients.
Li Z; Liu Y; Yi H; Cai T; Wei Y
Front Genet; 2022; 13():947747. PubMed ID: 36246627
[TBL] [Abstract][Full Text] [Related]
20. M6A-Related Long Non-Coding RNA Displays Utility in Predicting Prognosis, Portraying the Tumor Immune Microenvironment and Guiding Immunotherapy in Pancreatic Ductal Adenocarcinoma.
Xu G; Ji Y; Wang L; Xu H; Shen C; Ye H; Yang X
Vaccines (Basel); 2023 Feb; 11(3):. PubMed ID: 36992083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]